Notably, imatinib-treated patients showed reduced mRNA levels of HDACs 2, 6, and 8, linking HDAC overexpression to BCR-ABL-driven CML proliferation in vivo and supporting a dual-target strategy for HDACs and BCR-ABL. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.